InvestorsHub Logo
Followers 4
Posts 376
Boards Moderated 0
Alias Born 08/12/2014

Re: runncoach post# 7981

Thursday, 02/07/2019 8:41:29 AM

Thursday, February 07, 2019 8:41:29 AM

Post# of 21541
Valid points.

However, if we continue to compare to AXON, almost all of the market value was based on intepirdine. The share price collapsed from above $20 to $6 and then to $2 after two failures with the molecule.

Why did AXON get such a big valuation in the first place? I think it was because there is such a huge commercial potential for any valid Alzheimer's disease treatment that even with slim odds like they had it seemed like a good idea to invest in it with above 2 billion market cap.

Our situation here is actually far better IMHO when you look at the potential and odds of success. Sure, we have a big binary event coming up but so did AXON. That's the name of the game with most biotechs that don't have product(s) on the market.

As far as I can tell, all that is left is that AXON was light years better at marketing themselves compared to NTRP. Science and commercial potential wise we win hands down.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SNPX News